Cebashin Cap.
Forsythia Suspensa Fruit, Lonicera Japonica Whole, Mentha Arvensis Top, Platycodon Grandiflorus Root, Licorice, Arctium Lappa Fruit, Glycine Max Whole, Lophatherum Gracile Top, Schizonepeta Tenufolia Spike, Saiga Tatarica Horn
Chunwoo Pharmaceutical Co., Ltd.
Human Otc Drug
NDC 72850-0007Cebashin Cap. also known as Forsythia Suspensa Fruit, Lonicera Japonica Whole, Mentha Arvensis Top, Platycodon Grandiflorus Root, Licorice, Arctium Lappa Fruit, Glycine Max Whole, Lophatherum Gracile Top, Schizonepeta Tenufolia Spike, Saiga Tatarica Horn is a human otc drug labeled by 'Chunwoo Pharmaceutical Co., Ltd.'. National Drug Code (NDC) number for Cebashin Cap. is 72850-0007. This drug is available in dosage form of Capsule. The names of the active, medicinal ingredients in Cebashin Cap. drug includes Arctium Lappa Fruit - 356 mg/10g Forsythia Suspensa Fruit - 710 mg/10g Glycine Max Whole - 356 mg/10g Licorice - 426 mg/10g Lonicera Japonica Whole - 710 mg/10g Lophatherum Gracile Top - 284 mg/10g Mentha Arvensis Top - 426 mg/10g Platycodon Grandiflorus Root - 426 mg/10g Saiga Tatarica Horn - 22 mg/10g Schizonepeta Tenufolia Spike - 284 mg/10g . The currest status of Cebashin Cap. drug is Active.
Drug Information:
| Drug NDC: | 72850-0007 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Cebashin Cap. |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Forsythia Suspensa Fruit, Lonicera Japonica Whole, Mentha Arvensis Top, Platycodon Grandiflorus Root, Licorice, Arctium Lappa Fruit, Glycine Max Whole, Lophatherum Gracile Top, Schizonepeta Tenufolia Spike, Saiga Tatarica Horn |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Chunwoo Pharmaceutical Co., Ltd. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Capsule |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | ARCTIUM LAPPA FRUIT - 356 mg/10g
FORSYTHIA SUSPENSA FRUIT - 710 mg/10g
GLYCINE MAX WHOLE - 356 mg/10g
LICORICE - 426 mg/10g
LONICERA JAPONICA WHOLE - 710 mg/10g
LOPHATHERUM GRACILE TOP - 284 mg/10g
MENTHA ARVENSIS TOP - 426 mg/10g
PLATYCODON GRANDIFLORUS ROOT - 426 mg/10g
SAIGA TATARICA HORN - 22 mg/10g
SCHIZONEPETA TENUFOLIA SPIKE - 284 mg/10g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 12 Jan, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 09 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Chunwoo Pharmaceutical Co., Ltd.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | EA541308MV
P4793M1ES5
NID9NUV93F
61ZBX54883
UV4X7MQQ43
OY50I2L657
8J5Y2F7A5X
2DF0NS0O2Z
PU683NDA7H
2FN3BA1MZE
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 72850-0007-2 | 1 CAPSULE in 1 BOX (72850-0007-2) / 10 g in 1 CAPSULE (72850-0007-1) | 12 Jan, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose cold/cough aid
Product Elements:
Cebashin cap. forsythia suspensa fruit, lonicera japonica whole, mentha arvensis top, platycodon grandiflorus root, licorice, arctium lappa fruit, glycine max whole, lophatherum gracile top, schizonepeta tenufolia spike, saiga tatarica horn forsythia suspensa fruit forsythia suspensa fruit licorice licorice platycodon grandiflorus root platycodon grandiflorus root arctium lappa fruit arctium lappa fruit lactose monohydrate lonicera japonica whole lonicera japonica whole mentha arvensis top mentha arvensis top glycine max whole glycine max whole schizonepeta tenufolia spike schizonepeta tenufolia spike lophatherum gracile top lophatherum gracile top saiga tatarica horn saiga tatarica horn
Indications and Usage:
Uses a sore throat, thirst, cough, headache from a cold
Warnings:
Warnings do not use if you are children under 5 years old do not use if you have galactose intolerance lapp lactase deficiency glucose-galactose malabsorption (this medicine contains lactose) ask a doctor before use if you have hypertension have a heart disease or a kidney disease a patient with edema pregnant or have a chance to pregnant a patient who has rashes, bloodshot, redness, itching, and etc. caused by medication a patient with significantly weakened stomachs an elderly person (in general, elderly people should take with care, such as reducing their dosage, as their physiological function has deteriorated) in a post-disease stage (am abnormal reaction can be easily seen and the symptoms can worsen) a patient who is being treated by a doctor or are taking other medications stop use and ask a doctor, pharmacist or health professionals if if there is no improvement in symptoms after taking it for a few days you have following symptoms after use: - pseudohyperaldosteronism: reduce
Read more...d urine volume, swollen face, swollen hands and feet, heavy eyelids, firm hands, increased blood pressure, headache, and etc. (mediciness with a maximum daily dose of 1g or more may develop hypoglycemia, blood pressure rise, low sodium body fluid, edema, weight gain, and etc. caused by pseydohyperaldosteronism if taken continuously for a long time. therefore, make sufficient observations (measurement of serum potassium levels) and stop taking if there is any abnormality.) -myopathy: myopathy (muscle disease) may occur as a result of hypokalemia, so take sufficient observation and stop taking if you find any abnormalities such as feeling helplessness, limb cramps, paralysis, and etc. -skin trouble: a rash, itch, bloodshot, and etc. -digestive system disorder: anorexia, stomach discomfort, nausea, vomiting, and etc. other warnings do not take more than directed if children are to take this medicine, take it under the supervision of their guardian. when taken with potassium-containing agents, licorice-containing agents, glycirizinic acid or other related agents, loop diuretics (furosemide, ethacrynic acid), or thiazide diuretics (trichlormethiazide) and myopathy, it is likely to appear due to gastric aldosterone (pseudohyperaldosteronism) or hypokalemia if taken with other herbal medicines, be careful of overlapping of the crude medicines. in principle, you should not to take it continuously for a long time, but if it is necessary, consult with a doctor, herb doctor, dentist, pharmacist, or other health care professionals.
Dosage and Administration:
Directions for adults, take 1 packet per intake, 3 times a day, before or between meals
Package Label Principal Display Panel:
Cebashin cap. cebashin